These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 767112)

  • 61. Some immunologically based reactions that can cause the regression of large tumor masses.
    Alexander P
    Natl Cancer Inst Monogr; 1976 Nov; 44():105-8. PubMed ID: 799755
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of OK-432 on immunization with mitomycin-C-treated L1210 cells.
    Ryoyama K; Murayama T; Koshimura S
    Gan; 1979 Feb; 70(1):75-82. PubMed ID: 376388
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antitumor activity of hot-water extract from delipidated BCG.
    Sato H; Yokosawa A; Arai H; Nagai H; Kumano N; Motomiya M; Konno K
    Tohoku J Exp Med; 1978 Jul; 125(3):247-52. PubMed ID: 358496
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunotherapy models in experimental animals.
    Ferguson RM; Schmidtke JR
    Surg Clin North Am; 1979 Apr; 59(2):349-69. PubMed ID: 87018
    [No Abstract]   [Full Text] [Related]  

  • 65. Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria.
    Lamensans A; Chedid L; Lederer E; Rosselet JP; Gustafson RH; Spencer HJ; Ludwig B; Berger FM
    Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3656-60. PubMed ID: 171670
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combination chemo-immunotherapy with adriamycin in experimental tumor systems.
    Tagliabue A; Polentarutti N; Vecchi A; Mantovani A; Spreafico F
    Eur J Cancer (1965); 1977 Jul; 13(7):657-65. PubMed ID: 598392
    [No Abstract]   [Full Text] [Related]  

  • 67. Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guerin.
    Kollmorgen GM; Killion JJ; Sansing WA; Cantrell JL; Bundren JC; LeFever AV
    Surgery; 1976 Feb; 79(02):202-8. PubMed ID: 1108258
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunopotentiation with BCG. IV. Factors affecting the magnitude of an antitumor response.
    Hawrylko E; Mackaness GB
    J Natl Cancer Inst; 1973 Nov; 51(5):1683-8. PubMed ID: 4587143
    [No Abstract]   [Full Text] [Related]  

  • 69. Specific cytotoxic antibody in the sera of patients with melanoma.
    Kilpatrick RJ; Seigler HF
    J Surg Res; 1976 Nov; 21(5):301-5. PubMed ID: 794584
    [No Abstract]   [Full Text] [Related]  

  • 70. [Adjuvant immunotherapy with BCG for malignant brain tumors (author's transl)].
    Miki Y; Sano K; Takakura K; Mizutani H
    Neurol Med Chir (Tokyo); 1976 Jul; 16(4 pt 2):357-64. PubMed ID: 62316
    [No Abstract]   [Full Text] [Related]  

  • 71. Immunopotentiation with BCG. 3. Modulation of the response to a tumor-specific antigen.
    Hawrylko E; Mackaness GB
    J Natl Cancer Inst; 1973 Nov; 51(5):1677-82. PubMed ID: 4587142
    [No Abstract]   [Full Text] [Related]  

  • 72. BCG immunotherapy of rat tumors of defined immunogenicity.
    Baldwin RW; Pimm MV
    Natl Cancer Inst Monogr; 1973 Dec; 39():11-9. PubMed ID: 4595312
    [No Abstract]   [Full Text] [Related]  

  • 73. An endotoxin-induced serum factor that causes necrosis of tumors.
    Carswell EA; Old LJ; Kassel RL; Green S; Fiore N; Williamson B
    Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3666-70. PubMed ID: 1103152
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Active immunotherapy of L 1210 leukemia given after the graft of the tumor].
    Mathé G
    Rev Fr Etud Clin Biol; 1968 Nov; 13(9):881-3. PubMed ID: 5304470
    [No Abstract]   [Full Text] [Related]  

  • 75. The balance of host immunocompetence in chemical carcinogenesis and "nonspecific" immunotherapy.
    Hanna MG; Szakal AK; Peters LC
    Recent Results Cancer Res; 1975; (52):114-36. PubMed ID: 827793
    [No Abstract]   [Full Text] [Related]  

  • 76. Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. I. Treatment efficiency correlated to autoimmune reactivity.
    Olsson L; Ebbesen P
    J Immunol; 1979 Mar; 122(3):772-80. PubMed ID: 376705
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Immunochemistry of tubercle bacilli, with special reference to adjuvant activity (author's transl)].
    Azuma I
    Kekkaku; 1981 Dec; 56(12):595-607. PubMed ID: 7035731
    [No Abstract]   [Full Text] [Related]  

  • 78. BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case.
    Pliskin ME; Mastrangelo MJ; Bellet R; Berkelhammer J
    Oral Surg Oral Med Oral Pathol; 1976 Jul; 42(1):73-9. PubMed ID: 781579
    [No Abstract]   [Full Text] [Related]  

  • 79. [A review on mechanism of anti-tumor action of BCG (author's transl)].
    Tokunaga T
    Kekkaku; 1980 Aug; 55(8):351-7. PubMed ID: 6999202
    [No Abstract]   [Full Text] [Related]  

  • 80. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
    Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
    Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.